source
- Dr Cirstea on Sequencing Considerations in R/R Multiple MyelomaDiana Cirstea, MD, discusses sequencing considerations in relapsed/refractory multiple myeloma in the era of T-cell–redirecting therapies.onclive · 2mo ago↗ source
- Dr Hafron on the FDA Approval of Adjuvant Atezolizumab in MRD+ MIBCJason Hafron, MD, discusses the significance of the FDA approval of adjuvant atezolizumab for MRD+ muscle-invasive bladder cancer.onclive · 2mo ago↗ source
- CDER chief Høeg fired from FDA as other top roles turn overThe leader of the FDA's drug division, Tracy Beth Høeg, is expected to depart, as part of a broad shakeup at the top of the agency after the exit of now-former Commissioner Marty Makary, according ...Endpoints · 2mo ago